Mycophenolate mofetil

for immunosuppression

Recommendations from the MOH Drug Advisory Committee

Guidance Recommendations

The MOH Drug Advisory Committee has recommended to:

- ✓ Reclassify mycophenolate mofetil 250 mg capsule and 500 mg tablet from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
- ✓ List mycophenolate mofetil 500 mg powder for solution for infusion on the SDL

in view of favourable cost effectiveness compared to other immunosuppressants at the prices proposed by the manufacturer.

Subsidy status

SDL subsidy will apply for induction and maintenance treatment of active lupus nephritis and for all registered indications of mycophenolate mofetil in Singapore:

- Prophylaxis of acute organ rejection and treatment of refractory organ rejection in patients receiving allogeneic renal transplants,
- Prophylaxis of acute organ rejection and increased graft and patient survival in patients receiving allogeneic cardiac transplants, and
- Prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants.

Published on 1 September 2020

About the Agency

The Agency for Care Effectiveness (ACE) is the national health technology assessment agency in Singapore residing within the Ministry of Health. It conducts evaluations to inform the subsidy of treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. The guidance is based on the evidence available to the Committee as at 20 March 2020. This guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

Principal Head (HTA)
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg